Perioperative therapy for muscle invasive bladder cancer

Hematol Oncol Clin North Am. 2015 Apr;29(2):301-18, ix. doi: 10.1016/j.hoc.2014.11.002.

Abstract

Muscle invasive bladder cancer (MIBC) is an aggressive disease associated with poor survival rates. High rates of relapse, despite radical cystectomy, suggest that administration of systemic therapy in the perioperative period may improve clinical outcomes. Neoadjuvant treatment with cisplatin-based combination regimens is an established standard of care and has improved long-term survival in MIBC. As the use of neoadjuvant chemotherapy steadily increases, clinicians still need to decide about administering adjuvant chemotherapy to patients with high-risk disease. This review examines in detail the latest evidence available for both neoadjuvant and adjuvant chemotherapy, and highlights pertinent studies.

Keywords: Adjuvant therapy; Chemotherapy; Neoadjuvant therapy; Radical cystectomy; Radiotherapy; Urinary bladder neoplasms.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Humans
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Perioperative Care / methods*
  • Prognosis
  • Risk Assessment
  • Treatment Outcome
  • Urinary Bladder Neoplasms / diagnosis
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / therapy*